
Moderate to Severe Acne - Pipeline Insight, 2024
Description
Moderate to Severe Acne - Pipeline Insight, 2024
DelveInsight’s, “Moderate to Severe Acne - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Moderate to Severe Acne pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Moderate to Severe Acne: Overview
Acne is a skin disease that's often misunderstood. Some people believe that it's contagious or is caused by dirt; both of these allegations are untrue. There are a number of factors, like stress, that can contribute to acne. Hormonal changes can contribute to acne, so women may be more susceptible during pregnancy and menopause. The severity of acne is determined by the scope and type of lesions. Moderate acne is characterized by inflammatory (papules, pustules, nodules) and noninflammatory (comedones) lesions. Severe acne consists of numerous or extensive papules and pustules, as well as many nodules/cysts. Moderate to severe acne, which often warrants a more aggressive treatment than mild acne, is usually approached with a combination of topical treatments and oral antibiotics.
""Moderate to Severe Acne - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate to Severe Acne pipeline landscape is provided which includes the disease overview and Moderate to Severe Acne treatment guidelines. The assessment part of the report embraces, in depth Moderate to Severe Acne commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate to Severe Acne collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Moderate to Severe Acne.
- In the coming years, the Moderate to Severe Acne market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Moderate to Severe Acne R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Moderate to Severe Acne treatment market. Several potential therapies for Moderate to Severe Acne are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Moderate to Severe Acne market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Moderate to Severe Acne) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Moderate to Severe Acne report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Moderate to Severe Acne Emerging Drugs
- ASC40: Ascletis Pharma Inc.
- BTX 1503: Botanix Pharmaceuticals
Further product details are provided in the report……..
Moderate to Severe Acne: Therapeutic Assessment
This segment of the report provides insights about the different Moderate to Severe Acne drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Moderate to Severe Acne
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Moderate to Severe Acne: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate to Severe Acne therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate to Severe Acne drugs.
Moderate to Severe Acne Report Insights
- Moderate to Severe Acne Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Moderate to Severe Acne drugs?
- How many Moderate to Severe Acne drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate to Severe Acne?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate to Severe Acne therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Moderate to Severe Acne and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ascletis Pharma Inc.
- Botanix Pharmaceuticals
- Biofrontera Bioscience GmbH
- Novartis
- BIOPHARMX, INC.
- DERMATA THERAPEUTICS, INC
- AnaptysBio
- VYNE Therapeutics Inc.
- ASC40
- BTX 1503
- BF-200 ALA
- LYS006
- BPX-01
- DMT310
- Imsidolimab
- FCD105
Table of Contents
70 Pages
- Introduction
- Executive Summary
- Moderate to Severe Acne: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Moderate to Severe Acne – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ASC40: Ascletis Pharma Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Moderate to Severe Acne Key Companies
- Moderate to Severe Acne Key Products
- Moderate to Severe Acne- Unmet Needs
- Moderate to Severe Acne- Market Drivers and Barriers
- Moderate to Severe Acne- Future Perspectives and Conclusion
- Moderate to Severe Acne Analyst Views
- Moderate to Severe Acne Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.